得了这种病,吹肥皂泡都成了一种奢望!不是癌症的癌症,识别危险信号,早诊早治!

2018-01-10 佚名 健康时报

不能爬楼梯,一爬就气喘;不能干家务,一动就气喘,咳嗽;连吹肥皂泡也成了一种奢望。他们的肺仿佛被一张无形的网勒紧,束缚着他们的日常行动和生活。对于常人来说再自然不过的“呼吸”,却成为他们四处奔走、渴望达成的目标。

不能爬楼梯,一爬就气喘;不能干家务,一动就气喘,咳嗽;连吹肥皂泡也成了一种奢望。他们的肺仿佛被一张无形的网勒紧,束缚着他们的日常行动和生活。对于常人来说再自然不过的“呼吸”,却成为他们四处奔走、渴望达成的目标。

这些都是特发性肺纤维化(idiopathic pulmonary fibrosis,IPF)这种疾病患者的表现。

不是癌症,却比癌症生存率都低!

特发性肺纤维化属于间质性肺疾病的一种。它会使肺组织纤维化,形成永久疤痕,导致肺功能不可逆性的持续下降。由于认知率低,早期症状不明显,患者误诊率高,确诊时间晚,确诊后中位生存期仅2-3年 ,5年生存率低于30%,比大多数癌症的生存率都低,所以常被称作“不是癌症的癌症”。

在过去的二十年中,国内特发性肺纤维化发病率呈现逐步增加的趋势,且死亡率居高不下。据市场调研报告显示,我国IPF面临诊断率低、医院诊断水平参差不齐、抗肺纤维化治疗药物使用比例低的现状。

这种肺病一直缺乏权威数据!

然而,鉴于疾病本身的少见和学科发展的不平衡,特发性肺纤维化(IPF)的发病率在我国尚未有准确和权威的流行病学数据。

近日,由勃林格殷格翰支持、中华医学会呼吸病分会间质病学组组长、中日医院代华平教授牵头的“中国特发性肺纤维化疾病登记研究(PORTRAY)”在北京正式宣布启动,也是首个针对中国特发性肺纤维化患者的流行病学观察队列研究。

中国工程院院士、中国医师协会呼吸医师分会会长、中日医院王辰院长在研究启动会上表示,呼吸系统疾病是我国第一大类疾病,而呼吸疾病中鉴别诊断最难的就是间质性肺疾病,其中就包括特发性肺纤维化(IPF)。希望通过此次队列研究,能够填补国内特发性肺纤维化(IPF)疾病领域流行病学的空白,同时促进中国特发性肺纤维化诊治流程的标准化,提高诊治水平。


(图为王辰院士在中国特发性肺纤维化登记研究会上发言)

“目前欧洲、美国和日本针对特发性肺纤维化都做了相应的登记研究,而我国相对重视不够,在流行病学、疾病特征等方面都缺乏全面的资料。”代华平教授指出,“因此我们需要高质量的大数据来支撑认识这样危害大并且发病原因不是很清楚的疾病。”


(图为代华平教授在中国特发性肺纤维化登记研究会上发言)

该研究将历时5年多,建立特发性肺纤维化前瞻性队列,构建规范的临床数据库和生物标本库,描述 IPF的人口学特征与临床特征、自然病程、合并症与并发症特点、急性加重风险、患者生活质量、预后及影响因素,以及疾病负担等,筛查出预示IPF病情发展与转归的相关生物学标志物,在此基础上,建立IPF患者的规范管理体系和多中心协作网络。

识别危险信号,早诊早治!

研究显示:吸烟、空气污染、胃食管反流、家族史等是导致特发性肺纤维化的危险因素。

起初,患者通常没有症状或者仅有一些轻微的症状。随着疾病恶化,可能会出现干咳、气短、疲乏无力、经常感冒、杵状指、体重减轻等症状。

专家提醒,对于存在危险因素,并且有上述症状的人群,尤其是年龄超50岁的男性,应尽早到正规医院做个高分辨率的CT检查来明确诊断。

目前,高分辨率CT是早期诊断特发性肺纤维化的关键检查。高分辨率CT较普通CT可更明显、清晰地显示特发性肺纤维化患者肺部如蜘蛛网一样的小窝蜂阴影。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2060487, encodeId=59bc206048ef6, content=<a href='/topic/show?id=6b5e36e72d8' target=_blank style='color:#2F92EE;'>#危险信号#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36772, encryptionId=6b5e36e72d8, topicName=危险信号)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c25323, createdName=jambiya, createdTime=Sun Apr 08 21:03:00 CST 2018, time=2018-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=279695, encodeId=51d42e969583, content=谢谢了.学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Thu Jan 18 11:57:37 CST 2018, time=2018-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=278306, encodeId=24a42e8306c2, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d551998554, createdName=1e1c07bdm01(暂无匿称), createdTime=Sun Jan 14 06:54:23 CST 2018, time=2018-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1591217, encodeId=3a42159121e76, content=<a href='/topic/show?id=fcbf5950953' target=_blank style='color:#2F92EE;'>#早诊早治#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59509, encryptionId=fcbf5950953, topicName=早诊早治)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b90817925105, createdName=zsyan, createdTime=Fri Jan 12 14:03:00 CST 2018, time=2018-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=277487, encodeId=90ee2e748784, content=受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/01/11/843340fb4682f03b12c0770c09229692.jpg, createdBy=47aa2244654, createdName=121503aam61暂无昵称, createdTime=Thu Jan 11 09:30:36 CST 2018, time=2018-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=277340, encodeId=30082e734050, content=学习了很有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Thu Jan 11 00:42:16 CST 2018, time=2018-01-11, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2060487, encodeId=59bc206048ef6, content=<a href='/topic/show?id=6b5e36e72d8' target=_blank style='color:#2F92EE;'>#危险信号#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36772, encryptionId=6b5e36e72d8, topicName=危险信号)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c25323, createdName=jambiya, createdTime=Sun Apr 08 21:03:00 CST 2018, time=2018-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=279695, encodeId=51d42e969583, content=谢谢了.学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Thu Jan 18 11:57:37 CST 2018, time=2018-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=278306, encodeId=24a42e8306c2, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d551998554, createdName=1e1c07bdm01(暂无匿称), createdTime=Sun Jan 14 06:54:23 CST 2018, time=2018-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1591217, encodeId=3a42159121e76, content=<a href='/topic/show?id=fcbf5950953' target=_blank style='color:#2F92EE;'>#早诊早治#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59509, encryptionId=fcbf5950953, topicName=早诊早治)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b90817925105, createdName=zsyan, createdTime=Fri Jan 12 14:03:00 CST 2018, time=2018-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=277487, encodeId=90ee2e748784, content=受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/01/11/843340fb4682f03b12c0770c09229692.jpg, createdBy=47aa2244654, createdName=121503aam61暂无昵称, createdTime=Thu Jan 11 09:30:36 CST 2018, time=2018-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=277340, encodeId=30082e734050, content=学习了很有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Thu Jan 11 00:42:16 CST 2018, time=2018-01-11, status=1, ipAttribution=)]
    2018-01-18 txqjm

    谢谢了.学习

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2060487, encodeId=59bc206048ef6, content=<a href='/topic/show?id=6b5e36e72d8' target=_blank style='color:#2F92EE;'>#危险信号#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36772, encryptionId=6b5e36e72d8, topicName=危险信号)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c25323, createdName=jambiya, createdTime=Sun Apr 08 21:03:00 CST 2018, time=2018-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=279695, encodeId=51d42e969583, content=谢谢了.学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Thu Jan 18 11:57:37 CST 2018, time=2018-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=278306, encodeId=24a42e8306c2, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d551998554, createdName=1e1c07bdm01(暂无匿称), createdTime=Sun Jan 14 06:54:23 CST 2018, time=2018-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1591217, encodeId=3a42159121e76, content=<a href='/topic/show?id=fcbf5950953' target=_blank style='color:#2F92EE;'>#早诊早治#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59509, encryptionId=fcbf5950953, topicName=早诊早治)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b90817925105, createdName=zsyan, createdTime=Fri Jan 12 14:03:00 CST 2018, time=2018-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=277487, encodeId=90ee2e748784, content=受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/01/11/843340fb4682f03b12c0770c09229692.jpg, createdBy=47aa2244654, createdName=121503aam61暂无昵称, createdTime=Thu Jan 11 09:30:36 CST 2018, time=2018-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=277340, encodeId=30082e734050, content=学习了很有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Thu Jan 11 00:42:16 CST 2018, time=2018-01-11, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2060487, encodeId=59bc206048ef6, content=<a href='/topic/show?id=6b5e36e72d8' target=_blank style='color:#2F92EE;'>#危险信号#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36772, encryptionId=6b5e36e72d8, topicName=危险信号)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c25323, createdName=jambiya, createdTime=Sun Apr 08 21:03:00 CST 2018, time=2018-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=279695, encodeId=51d42e969583, content=谢谢了.学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Thu Jan 18 11:57:37 CST 2018, time=2018-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=278306, encodeId=24a42e8306c2, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d551998554, createdName=1e1c07bdm01(暂无匿称), createdTime=Sun Jan 14 06:54:23 CST 2018, time=2018-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1591217, encodeId=3a42159121e76, content=<a href='/topic/show?id=fcbf5950953' target=_blank style='color:#2F92EE;'>#早诊早治#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59509, encryptionId=fcbf5950953, topicName=早诊早治)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b90817925105, createdName=zsyan, createdTime=Fri Jan 12 14:03:00 CST 2018, time=2018-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=277487, encodeId=90ee2e748784, content=受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/01/11/843340fb4682f03b12c0770c09229692.jpg, createdBy=47aa2244654, createdName=121503aam61暂无昵称, createdTime=Thu Jan 11 09:30:36 CST 2018, time=2018-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=277340, encodeId=30082e734050, content=学习了很有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Thu Jan 11 00:42:16 CST 2018, time=2018-01-11, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2060487, encodeId=59bc206048ef6, content=<a href='/topic/show?id=6b5e36e72d8' target=_blank style='color:#2F92EE;'>#危险信号#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36772, encryptionId=6b5e36e72d8, topicName=危险信号)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c25323, createdName=jambiya, createdTime=Sun Apr 08 21:03:00 CST 2018, time=2018-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=279695, encodeId=51d42e969583, content=谢谢了.学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Thu Jan 18 11:57:37 CST 2018, time=2018-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=278306, encodeId=24a42e8306c2, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d551998554, createdName=1e1c07bdm01(暂无匿称), createdTime=Sun Jan 14 06:54:23 CST 2018, time=2018-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1591217, encodeId=3a42159121e76, content=<a href='/topic/show?id=fcbf5950953' target=_blank style='color:#2F92EE;'>#早诊早治#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59509, encryptionId=fcbf5950953, topicName=早诊早治)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b90817925105, createdName=zsyan, createdTime=Fri Jan 12 14:03:00 CST 2018, time=2018-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=277487, encodeId=90ee2e748784, content=受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/01/11/843340fb4682f03b12c0770c09229692.jpg, createdBy=47aa2244654, createdName=121503aam61暂无昵称, createdTime=Thu Jan 11 09:30:36 CST 2018, time=2018-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=277340, encodeId=30082e734050, content=学习了很有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Thu Jan 11 00:42:16 CST 2018, time=2018-01-11, status=1, ipAttribution=)]
    2018-01-11 121503aam61暂无昵称

    受益

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2060487, encodeId=59bc206048ef6, content=<a href='/topic/show?id=6b5e36e72d8' target=_blank style='color:#2F92EE;'>#危险信号#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36772, encryptionId=6b5e36e72d8, topicName=危险信号)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c25323, createdName=jambiya, createdTime=Sun Apr 08 21:03:00 CST 2018, time=2018-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=279695, encodeId=51d42e969583, content=谢谢了.学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Thu Jan 18 11:57:37 CST 2018, time=2018-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=278306, encodeId=24a42e8306c2, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d551998554, createdName=1e1c07bdm01(暂无匿称), createdTime=Sun Jan 14 06:54:23 CST 2018, time=2018-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1591217, encodeId=3a42159121e76, content=<a href='/topic/show?id=fcbf5950953' target=_blank style='color:#2F92EE;'>#早诊早治#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59509, encryptionId=fcbf5950953, topicName=早诊早治)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b90817925105, createdName=zsyan, createdTime=Fri Jan 12 14:03:00 CST 2018, time=2018-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=277487, encodeId=90ee2e748784, content=受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/01/11/843340fb4682f03b12c0770c09229692.jpg, createdBy=47aa2244654, createdName=121503aam61暂无昵称, createdTime=Thu Jan 11 09:30:36 CST 2018, time=2018-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=277340, encodeId=30082e734050, content=学习了很有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Thu Jan 11 00:42:16 CST 2018, time=2018-01-11, status=1, ipAttribution=)]
    2018-01-11 飛歌

    学习了很有用

    0

相关资讯

Respir Med:吡非尼酮治疗特发性肺纤维化急性加重是否有效?

作为全球首个获得特发性肺纤维化(IPF)适应症的药物,吡非尼酮目前已被大家熟知。但其对特发性肺纤维化急性加重(AE-IPF)的有效性尚不清楚。2017年5月,发表在《Respir Med》的一项由日本科学家进行的回顾性研究考察了吡非尼酮对AE-IPF的有效性。背景:AE-IPF是一种快速且最终致命的病症,尚未建立有效的治疗方法。吡非尼酮在IPF中具有抗纤维化作用;然而,其对AE-IPF的有效性尚不

Cell Death Dis:研究发现lnc-PCF或是肺纤维化的治疗靶点

近期研究表明microRNA(miRNA)和长链非编码RNA(lncRNA)在疾病的发展中起重要作用。然而,mRNA与miRNA和lncRNA在特发性肺纤维化(IPF)中相互作用的机制仍不清楚。本研究通过在肺纤维化过程中直接靶向miR-344a-5p,通过调节map3k11促进TGF-β1活化的上皮细胞的增殖,展示了一种新的Lnc-PCF。然后进行生物信息学和体外翻译测定以确认lnc-PCF是否是

Respir Res:有趣的圣乔治呼吸问卷

目前尚不清楚健康相关的生活质量(HRQL)是否具有预测特发性肺纤维化(IPF)死亡率的价值。近期,一项发表在Respir Res杂志上的研究使用圣乔治呼吸问卷(SGRQ)评估HRQL与IPF患者的生存时间之间的关系,并尝试确定临床有意义的临界值以预测更差的存活率。此项研究回顾性分析了2007年5月至2012年12月接受初步评估的IPF患者。根据2011年国际共识指南进行IPF的诊断。研究者们使用C

重磅:抗肺纤维化创新靶向药尼达尼布获批,将为国内特发性肺纤维化治疗带来重大突破

勃林格殷格翰昨天宣布,其自主研发的抗肺纤维化创新靶向药维加特®(尼达尼布),已获得国家食品药品监督管理总局(CFDA)颁发的进口药品注册证,被批准用于治疗特发性肺纤维化(IPF)。该新药的获批为中国IPF患者提供了全新的治疗选择,可有效延缓疾病进展,减少急性加重风险,改善生活质量;同时也有助于推动我国IPF的诊断和治疗水平的提高。

Respirology:吡非尼酮和尼达尼布治疗肺纤维化:耐受性和不良药物反应

吡非尼酮和尼达尼布在非临床试验患者中的真实世界的耐受性尚未得知。2017年8月,发表在《Respirology》的一项回顾性图表审查研究调查了临床实践中,吡非尼酮和尼达尼布治疗肺纤维化的耐受性和不良药物反应。

Autophagy:抗癌药物博来霉素为何会导致肺纤维化?

博莱霉素是一种有效的临床抗癌药物,用于治疗生殖细胞肿瘤,淋巴瘤和鳞状细胞癌。不幸的是,博莱霉素的治疗效果受到肺纤维化发展的严重阻碍。